Display options
Cite
Abe Y, Iba K, Takada J, et al. Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series. J Med Case Rep. 2011;5:349doi: 10.1186/1752-1947-5-349.
Abe, Y., Iba, K., Takada, J., Wada, T., & Yamashita, T. (2011). Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series. Journal of medical case reports, 5349. https://doi.org/10.1186/1752-1947-5-349
Abe, Yasuhisa, et al. "Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series." Journal of medical case reports vol. 5 (2011): 349. doi: https://doi.org/10.1186/1752-1947-5-349
Abe Y, Iba K, Takada J, Wada T, Yamashita T. Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series. J Med Case Rep. 2011 Aug 04;5:349. doi: 10.1186/1752-1947-5-349. PMID: 21816057; PMCID: PMC3163217.
Copy Download .nbib Format: NLM
Share it on

J Med Case Rep. 2011 Aug 04;5:349. doi: 10.1186/1752-1947-5-349.

Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series.

Journal of medical case reports

Yasuhisa Abe, Kousuke Iba, Junichi Takada, Takuro Wada, Toshihiko Yamashita

Affiliations

  1. Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan. [email protected].

PMID: 21816057 PMCID: PMC3163217 DOI: 10.1186/1752-1947-5-349

Abstract

INTRODUCTION: Complex regional pain syndrome is characterized by pain, allodynia, hyperalgesia, edema, signs of vasomotor instability, movement disorders, joint stiffness, and regional osteopenia. It is recognized to be difficult to treat, despite various methods of treatment, including physiotherapy, calcitonin, corticosteroids, sympathetic blockade, and nonsteroidal anti-inflammatory drugs. Pathophysiologically, complex regional pain syndrome reveals enhanced regional bone resorption and high bone turnover, and so bisphosphonates, which have a potent inhibitory effect on bone resorption, were proposed for the treatment of complex regional pain syndrome.

CASE PRESENTATION: A 48-year-old Japanese man with complex regional pain syndrome type I had severe right ankle pain with a visual analog scale score of 59 out of 100 regardless of treatment with physiotherapy and nonsteroidal anti-inflammatory drugs for five months. Radiographs showed marked regional osteoporotic changes and bone scintigraphy revealed a marked increase in radioactivity in his ankle. One month after the start of oral administration of risedronate (2.5 mg per day), his bone pain had fallen from a VAS score of 59 out of 100 to 18 out of 100. Bone scintigraphy at 12 months showed a marked reduction in radioactivity to a level comparable to that in his normal, left ankle. On the basis of these results, the treatment was discontinued at 15 months. At 32 months, our patient had almost no pain and radiographic findings revealed that the regional osteoporotic change had returned to normal.A second 48-year-old Japanese man with complex regional pain syndrome type I had severe right foot pain with a visual analog scale score of 83 out of 100 regardless of treatment with physiotherapy and nonsteroidal anti-inflammatory drugs for nine months. Radiographs showed regional osteoporotic change in his phalanges, metatarsals, and tarsals, and bone scintigraphy revealed a marked increase in radioactivity in his foot. One month after the start of oral administration of alendronate (35 mg per week), his bone pain had fallen from a visual analog scale score of 83 out of 100 to 30 out of 100 and, at nine months, was further reduced to 3 out of 100. The treatment was discontinued at 15 months because of successful pain reduction. At 30 months, our patient had no pain and the radiographic findings revealed marked improvement in regional osteoporotic changes.

CONCLUSIONS: We believe low-dose oral administration of bisphosphonate is worth considering for the treatment of idiopathic complex regional pain syndrome type I accompanied by regional osteoporotic change.

References

  1. Pain. 2010 Aug;150(2):243-249 - PubMed
  2. Lancet. 1997 Oct 18;350(9085):1117 - PubMed
  3. Arthritis Rheum. 2004 Nov;50(11):3690-7 - PubMed
  4. Ann Rheum Dis. 1997 Mar;56(3):201-4 - PubMed
  5. J Bone Miner Res. 2006 Dec;21 Suppl 2:P94-8 - PubMed
  6. Eur J Pain. 2002;6(2):105-22 - PubMed
  7. Clin Rheumatol. 1988 Jun;7(2):173-80 - PubMed
  8. Clin J Pain. 1998 Jun;14(2):155-66 - PubMed
  9. Ann Rheum Dis. 1995 Aug;54(8):687 - PubMed
  10. Lancet. 1993 Oct 23;342(8878):1012-6 - PubMed
  11. J Oral Maxillofac Surg. 2009 Dec;67(12):2698-9 - PubMed
  12. Lancet Neurol. 2003 Nov;2(11):687-97 - PubMed
  13. Hand Clin. 1997 Aug;13(3):443-54 - PubMed
  14. Bone. 2003 Oct;33(4):567-74 - PubMed
  15. N Engl J Med. 2008 Mar 20;358(12):1304-6 - PubMed
  16. J Rheumatol. 2000 Jun;27(6):1477-83 - PubMed
  17. Bone. 2006 Nov;39(5):1107-1115 - PubMed
  18. J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301 - PubMed
  19. Rheumatology (Oxford). 2001 Dec;40(12):1394-7 - PubMed
  20. Curr Opin Rheumatol. 1994 Mar;6(2):210-6 - PubMed

Publication Types